Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Sarah W. Read"'
Autor:
Que Dang, Katrin Eichelberg, Nancy Vázquez-Maldonado, César Boggiano, Wolfgang W. Leitner, Lakshmi Ramachandra, Alison Deckhut-Augustine, Sarah W. Read
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/0254398e6684482d95355c923af73bc4
Autor:
Thomas Calder, Tina Tong, Dale J. Hu, Jerome H. Kim, Karen L. Kotloff, Richard A. Koup, Mary A. Marovich, M. Juliana McElrath, Sarah W. Read, Merlin L. Robb, Philip O. Renzullo, M. Patricia D’Souza
Publikováno v:
Communications Medicine, Vol 2, Iss 1, Pp 1-8 (2022)
Calder, Tong et al. discuss how the rapid development of COVID-19 vaccines benefited from HIV/AIDS research. They highlight lessons learned from the COVID-19 vaccine development experience that could accelerate and re-energize the development of a sa
Externí odkaz:
https://doaj.org/article/e08e8fd66aa342dda7b05432934e0c1b
Publikováno v:
Journal of the International AIDS Society, Vol 25, Iss 12, Pp n/a-n/a (2022)
Externí odkaz:
https://doaj.org/article/1ff733c9adb84f10a695fbbc76bc206c
Autor:
Lisa M. LaVange, Judith S. Currier, Lora A. Reineck, Eric A Hughes, Sarah W. Read, Elizabeth S. Higgs, Stacey J Adam
Publikováno v:
Annals of Internal Medicine
Despite the development of highly effective SARS-CoV-2 vaccines, there remains a great need for effective treatment of COVID-19. Through a public–private partnership in the United States, a system has been created to efficiently test a variety of t
Autor:
Joseph P. Menetski, Eric A Hughes, Joshua P. Fessel, Stacey J Adam, Timothy G. Buchman, Ruxandra Draghia-Akli, Sarah W. Read, Elizabeth S. Higgs, Neil R. Aggarwal
Publikováno v:
Critical Care Medicine
Supplemental Digital Content is available in the text.
Given the urgent need for coronavirus disease 2019 therapeutics, early in the pandemic the Accelerating Coronavirus Disease 2019 Therapeutic Interventions and Vaccines (ACTIV) public-private
Given the urgent need for coronavirus disease 2019 therapeutics, early in the pandemic the Accelerating Coronavirus Disease 2019 Therapeutic Interventions and Vaccines (ACTIV) public-private
Autor:
Maurine D Miner, Mark Hatherill, Vidya Mave, Glenda E Gray, Sharon Nachman, Sarah W Read, Richard G White, Anneke Hesseling, Frank Cobelens, Sheral Patel, Mike Frick, Theodore Bailey, Robert Seder, Joanne Flynn, Jyothi Rengarajan, Deepak Kaushal, Willem Hanekom, Alexander C Schmidt, Thomas J Scriba, Elisa Nemes, Erica Andersen-Nissen, Alan Landay, Susan E Dorman, Grace Aldrovandi, Lisa M Cranmer, Cheryl L Day, Alberto L Garcia-Basteiro, Andrew Fiore-Gartland, Robin Mogg, James G Kublin, Amita Gupta, Gavin Churchyard
Publikováno v:
The lancet. HIV. 9(11)
New tuberculosis vaccine candidates that are in the development pipeline need to be studied in people with HIV, who are at high risk of acquiring Mycobacterium tuberculosis infection and tuberculosis disease and tend to develop less robust vaccine-in
Publikováno v:
J Infect Dis
This article outlines the significant scientific progress reported in 2019 that has led to the development of new drugs and therapeutic regimens, vaccine candidates, and diagnostics for the prevention and treatment of tuberculosis. In 2020, it will b
Publikováno v:
JAMA. 324:2149
Autor:
David B. Clifford, Charles Flexner, Minhee Kang, Daniel C. Douek, Lynette Purdue, Alan L. Landay, Sarah W. Read, Jeffrey M. Jacobson, Princy Kumar, Brian Clagett, Laurie Myers, Michael M. Lederman, Pablo F. Belaunzarán-Zamudio, Steven E. Bosinger, Cara C. Wilson, Pablo Tebas, Roy M. Matining, Guido Silvestri, Linda Boone, Jill Plants
Publikováno v:
AIDS Research and Human Retroviruses. 32:636-647
Immune activation associated with HIV-1 infection contributes to morbidity and mortality. We studied whether chloroquine, through Toll-like receptor (TLR) antagonist properties, could reduce immune activation thought to be driven by TLR ligands, such
Autor:
Bernard J.C. Macatangay, Robbie B. Mailliard, Paula W. Annunziato, Cheryl Jennings, Marshall J. Glesby, Dawn R Bozzolo, Sarah W. Read, Charles R. Rinaldo, Janet Andersen, Lynette Purdue, Jason C. Martin, Amy Falk Russell, Zoran Popmihajlov, Constance A. Benson, Michael C. Keefer, Pablo Tebas, Jeffrey L. Lennox
BACKGROUND: Herpes zoster (HZ) risk is increased in human immunodeficiency virus (HIV)–infected persons. Live attenuated zoster vaccine (ZV) reduces HZ incidence and severity in adults; safety and immunogenicity data in HIV-infected adults are limi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfdf7f6fe1e24665ed807cbda51d5c7f
https://europepmc.org/articles/PMC6233680/
https://europepmc.org/articles/PMC6233680/